Berwyn, Pennsylvania, November 2, 2015 – Maria Maccecchini, PhD, President and CEO of QR Pharma, Inc. is presenting a paper entitled “Analysis of Multiple Biomarkers and Factors in Blood and CSF in Phase 2 to Facilitate Choice of End Points in Phase 3” is part of a Forum on CNS Clinical Trials. The presentation is […]
Ben Franklin Technology Partners – QR Pharma Focuses on Treatments for Alzheimer�s and Dementia Related to Down Syndrome – May 2010 Article >>>>>
Berwyn, PA, October 13, 2011 QR Pharma, Inc., a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer’s disease (AD), along with the Medical University of South Carolina (MUSC) report on the results obtained from the Small Business Innovation Research (SBIR) phase I grant study
Berwyn, Pa., April 8, 2015/PRNewswire/ — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced that it was issued U.S. Patent No. 8,691,864, “Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia” by the U.S. Patent and Trademark Office. The “864
Radnor, PA, April 6, 2009 QR Pharma, Inc., a newly formed specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease, received a $500,000 investment from Ben Franklin Technology Partners of Southeastern PA. The investment will further the clinical development of two lines of compounds, Posiphen® and bisnorcymserine and their respective
Berwyn, PA., October 27, 2016 — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, has closed on $800,000 of Series A Preferred Stock financing. Existing investors Robin Hood Ventures and individual angels filled this round. QR Pharma will use the funding to
Berwyn, PA, September 20, 2012: QR Pharma, Inc., a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders presented at the University of Pennsylvania in Rod and Maryellen Eckenhoff’sAnesthesia department. Dr. Maccecchini discussed the most recent developments and
Berwyn, PA., May 26, 2015 — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, has closed on $5.7 M of Series A Preferred Stock financing. The round was comprised of $1.1 M of new investments and the conversion of convertible debt. QR
–President and CEO, Dr. Maria Maccecchini, to Speak in Panel– Berwyn, Pa., October 4, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., President and CEO, will participate in the Neuro Advance Boston
–Posiphen Restores Memory and Learning and Brain Function as well as Gut Motility and Coordination in Mice Models of AD and PD– Berwyn, Pa., March 16, 2017 — QR Pharma, Inc., a privately held phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s (AD), Parkinson’s (PD) and other neurodegenerative diseases, today announced
